Reimbursement of a second biosimilar infliximab could provide welcome savings in a health system struggling with high drug costs.
The Canadian province of British Columbia will now reimburse for Renflexis, a biosimilar infliximab, under its public drug plan, Merck has announced. The biosimilar is approved in Canada to treat a range of disorders, including inflammatory bowel diseases and inflammatory arthritis.
"We are pleased to see the government of British Columbia add Renflexis to its formulary, which offers effective and more affordable treatment options for patients impacted by these diseases," say Manon Lafontaine, vice president of patient access for Merck Canada, in a statement. "We're committed to continuing to work with provinces and territories throughout Canada to ensure broader access for all patients to the care they need."
The announcement follows the Canadian Agency for Drugs and Technologies in Health recommendation in February 2018 that the biosimilar be reimbursed for patients for whom infliximab is the most appropriate treatment option.
Read more about biosimilars in Canada.
Like the reference infliximab, Remicade, and another biosimilar, Inflectra, Renflexis has been classed as a Limited Coverage Drug in British Columbia, which means that it will not generally be considered for first-line therapy. Special criteria apply for the prescribing of infliximab in any of its approved indications through British Columbia’s PharmaCare drug coverage plan.
Reimbursement of a second biosimilar infliximab could provide welcome savings in a health system struggling with high drug costs; the latest annual report from Canada’s Patented Medicines Prices Review Board (PMPRB), released just last week, indicated that the average annual treatment cost for patients receiving brand-name infliximab grew from CaD $17,759 in 2006 (approximately US $13,708) to CaD $28,804 in 2017 (approximately US $22,234).
High-cost immunosuppressive biologics in general have seen a swift uptake in the Canadian market, driven primarily by brand-name Remicade, adalimumab (Humira), and etanercept (Enbrel), says the report. These products accounted for 4% of all patented medicine sales in 2008, but rose to 17% by 2017.
Renflexis is also approved by the FDA and is available in the United States.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.